Viewing Study NCT07156435

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:45 PM
Ignite Modification Date: 2026-01-28 @ 1:39 PM
Study NCT ID: NCT07156435
Status: RECRUITING
Last Update Posted: 2025-09-05
First Post: 2025-08-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Vyxeos® With Clofarabine for Pediatric AML
Sponsor: Princess Maxima Center for Pediatric Oncology
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed Pediatric AML View
None Refractory Pediatric AML View
Keywords:

Keywords

Keyword Brief Keyword Text View
None pediatric AML View
None relapsed/refractory View
None clofarabine View
None liposomal daunorubicin and cytarabine View